[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX361538B - Compuestos quimicos. - Google Patents

Compuestos quimicos.

Info

Publication number
MX361538B
MX361538B MX2015016428A MX2015016428A MX361538B MX 361538 B MX361538 B MX 361538B MX 2015016428 A MX2015016428 A MX 2015016428A MX 2015016428 A MX2015016428 A MX 2015016428A MX 361538 B MX361538 B MX 361538B
Authority
MX
Mexico
Prior art keywords
chemical compounds
pharmaceutically
processes
formula
preparation
Prior art date
Application number
MX2015016428A
Other languages
English (en)
Other versions
MX2015016428A (es
Inventor
Akhtar Nadim
Hugh Bradbury Robert
Buttar David
Stuart Currie Gordon
De Savi Christopher
Samuel Donald Craig
Albert Norman Richard
Osborne Matthew
Arthur Rabow Alfred
Marie Redfearn Heather
Elizabeth Williams Helen
Yavari Neda
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2015016428A publication Critical patent/MX2015016428A/es
Publication of MX361538B publication Critical patent/MX361538B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invención se refiere a compuestos de Fórmula (I): (ver Fórmula) o sales farmacéuticamente aceptables de estos, en donde R1 a R5 tienen cualquiera de los significados que se definen anteriormente en la descripción de la presente; procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en el tratamiento de trastornos proliferativos celulares.
MX2015016428A 2013-05-28 2014-05-27 Compuestos quimicos. MX361538B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361827951P 2013-05-28 2013-05-28
US201361915685P 2013-12-13 2013-12-13
PCT/GB2014/051607 WO2014191726A1 (en) 2013-05-28 2014-05-27 Chemical compounds

Publications (2)

Publication Number Publication Date
MX2015016428A MX2015016428A (es) 2016-03-03
MX361538B true MX361538B (es) 2018-12-10

Family

ID=50841880

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016428A MX361538B (es) 2013-05-28 2014-05-27 Compuestos quimicos.

Country Status (35)

Country Link
US (4) US9155727B2 (es)
EP (2) EP3360875A1 (es)
JP (1) JP6286031B2 (es)
KR (1) KR20160013198A (es)
CN (1) CN105229004B (es)
AP (1) AP2015008858A0 (es)
AU (1) AU2014272856B2 (es)
BR (1) BR112015029455A8 (es)
CA (1) CA2911859A1 (es)
CL (1) CL2015003491A1 (es)
CR (1) CR20150629A (es)
CY (1) CY1120474T1 (es)
DK (1) DK3004090T3 (es)
DO (1) DOP2015000274A (es)
ES (1) ES2654161T3 (es)
HK (1) HK1222859A1 (es)
HR (1) HRP20171961T1 (es)
HU (1) HUE035738T2 (es)
IL (1) IL242559B (es)
LT (1) LT3004090T (es)
ME (1) ME02892B (es)
MX (1) MX361538B (es)
NI (1) NI201500167A (es)
PE (1) PE20160874A1 (es)
PH (1) PH12015502615B1 (es)
PL (1) PL3004090T3 (es)
PT (1) PT3004090T (es)
RS (1) RS56678B1 (es)
RU (1) RU2664109C2 (es)
SG (1) SG11201509393VA (es)
SI (1) SI3004090T1 (es)
TN (1) TN2015000516A1 (es)
TW (1) TWI653235B (es)
UY (1) UY35590A (es)
WO (1) WO2014191726A1 (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101939710B1 (ko) 2011-12-21 2019-01-17 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
AR092269A1 (es) 2012-08-28 2015-04-08 Janssen R&D Ireland Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
DK2961732T3 (en) 2013-02-28 2017-07-10 Janssen Sciences Ireland Uc SULFAMOYLARYLAMIDS AND USE THEREOF AS MEDICINES TO TREAT HEPATITIS B
DK2981536T3 (en) 2013-04-03 2017-09-25 Janssen Sciences Ireland Uc N-PHENYLC CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
AU2014267235B2 (en) 2013-05-17 2017-10-05 Janssen Sciences Ireland Uc Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CN108047115B (zh) 2013-07-25 2021-06-29 爱尔兰詹森科学公司 经乙醛酰胺取代的吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
AP2016009122A0 (en) 2013-10-23 2016-03-31 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
ES2792848T3 (es) 2014-02-05 2020-11-12 Novira Therapeutics Inc Politerapia para el tratamiento de infecciones por VHB
DK3102572T3 (en) 2014-02-06 2019-02-04 Janssen Sciences Ireland Uc SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B
EP3233852B1 (en) * 2014-12-18 2020-07-15 F. Hoffmann-La Roche AG Tetrahydro-pyrido[3,4-b]indoles as estrogen receptor modulators and uses thereof
WO2016146591A1 (en) * 2015-03-16 2016-09-22 Astrazeneca Ab Combination treatment
EP3271019A1 (en) 2015-03-19 2018-01-24 Novira Therapeutics Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
KR20180012853A (ko) * 2015-06-16 2018-02-06 지앙수 헨그루이 메디슨 컴퍼니 리미티드 피페리딘 유도체 및 이의 제조 방법 및 약학적 용도
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CA2995036A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
JP6845231B2 (ja) 2015-09-29 2021-03-17 ノヴィラ・セラピューティクス・インコーポレイテッド Ｂ型肝炎抗ウイルス薬の結晶形態
RU2021107754A (ru) * 2015-10-01 2021-04-01 Олема Фармасьютикалз, Инк. ТЕТРАГИДРО-1H-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА
US10519148B2 (en) 2015-11-12 2019-12-31 Zhejiang Hisun Pharmaceutical Co., Ltd. Acrylic acid derivative, preparation method and use in medicine thereof
PT3386500T (pt) 2015-12-09 2023-01-06 Univ Illinois Supressores seletivos do recetor de estrogénio à base de benzotiofeno
CN107428721B (zh) 2015-12-22 2020-07-28 江苏恒瑞医药股份有限公司 苯并哌啶类衍生物、其制备方法及其在医药上的应用
US10647724B2 (en) * 2016-02-05 2020-05-12 Inventisbio Inc. Selective estrogen receptor degraders and uses thereof
IL295050A (en) * 2016-04-01 2022-09-01 Recurium Ip Holdings Llc Estrogen receptor modulators
JP2019511542A (ja) 2016-04-15 2019-04-25 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カプシド集合阻害剤を含む組み合わせ及び方法
TW201803870A (zh) 2016-04-20 2018-02-01 阿斯特捷利康公司 化學化合物
PL3449017T3 (pl) * 2016-04-29 2022-06-27 Board Of Regents, The University Of Texas System Ukierunkowane pomiary aktywności transkrypcyjnej związanej z receptorami hormonów
CN109661393A (zh) * 2016-05-08 2019-04-19 上海诚妙医药科技有限公司 帕布昔利布的新晶型及其制备方法及其用途
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
WO2017216280A1 (en) 2016-06-16 2017-12-21 F. Hoffmann-La Roche Ag TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
EP3472162B1 (en) * 2016-06-16 2021-11-17 F. Hoffmann-La Roche AG Heteroaryl estrogen receptor modulators and uses thereof
WO2018001232A1 (zh) * 2016-06-29 2018-01-04 浙江海正药业股份有限公司 丙烯酸类衍生物及其制备方法和其在医药上的用途
WO2018005860A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
US10149839B2 (en) 2016-07-25 2018-12-11 Astrazeneca Ab Chemical compounds
CN107814798B (zh) * 2016-09-14 2020-11-03 四川科伦博泰生物医药股份有限公司 3-取代丙烯酸类化合物及其制备方法和用途
CN110139674B (zh) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
ME03547B (me) 2016-10-24 2020-07-20 Astrazeneca Ab Derivat 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izohinolina koristan u tretmanu rаkа
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
NZ754865A (en) 2017-01-06 2023-07-28 G1 Therapeutics Inc Combination therapy for the treatment of cancer
WO2018130123A1 (zh) * 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的五环类化合物及其应用
WO2018130124A1 (zh) * 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的三环类化合物及其应用
JOP20190183B1 (ar) * 2017-01-30 2022-09-15 Astrazeneca Ab معدِلات مستقبلات الاستروجين
JP7227912B2 (ja) 2017-02-08 2023-02-24 ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド キメラ抗原受容体の調節
KR20190117582A (ko) 2017-02-10 2019-10-16 쥐원 쎄라퓨틱스, 인크. 벤조티오펜 에스트로겐 수용체 조정제
CN108864080B (zh) * 2017-05-09 2021-10-15 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的四环类化合物及其应用
CN110536888B (zh) * 2017-06-20 2022-07-26 江苏恒瑞医药股份有限公司 一种苯并哌啶类衍生物的盐、其晶型及盐、其晶型的制备方法
KR102659211B1 (ko) 2017-06-29 2024-04-18 쥐원 쎄라퓨틱스, 인크. G1t38의 형체 형태 및 그의 제조 방법
BR112020007576A2 (pt) 2017-10-18 2020-09-24 Novartis Ag composições e métodos para degradação de proteína seletiva
EA038160B1 (ru) * 2017-11-30 2021-07-15 Астразенека Аб Модуляторы рецептора эстрогена
CN109867659A (zh) * 2017-12-04 2019-06-11 江苏恒瑞医药股份有限公司 苯并哌啶类衍生物的制备方法
US10519152B2 (en) 2017-12-21 2019-12-31 Astrazeneca Ab Compounds and their use in treating cancer
EP3755683A1 (en) * 2018-02-23 2020-12-30 Center for Intelligent Research in Crystal Engineering, S.L. Cocrystals of ubiquinol and compositions comprising them
CR20200378A (es) 2018-03-14 2021-01-08 Janssen Sciences Ireland Unlimited Co Régimen posológico del modulador del emsalblaje de la cápside
TW202016084A (zh) * 2018-05-30 2020-05-01 大陸商迪哲（江蘇）醫藥有限公司 選擇性雌激素受體下調劑和其用途
UA128114C2 (uk) 2018-06-21 2024-04-10 Ф. Хоффманн-Ля Рош Аг Тверді форми 3-((1r,3r)-1-(2,6-дифтор-4-((1-(3-фторпропіл)азетидин-3-іл)аміно)феніл)-3-метил-1,3,4,9-тетрагідро-2h-піридo[3,4-b]індол-2-іл)-2,2-дифторпропан-1-олу і способи одержання конденсованих трициклічних сполук, що містять заміщене фенільне або піридинільне угруповання, в тому числі способи їх застосування
US20210276951A1 (en) 2018-07-03 2021-09-09 The Board Of Trustees Of The University Of Illinois Activators of the unfolded protein response
CN113453679A (zh) 2018-12-20 2021-09-28 C4医药公司 靶向蛋白降解
AU2018454987A1 (en) 2018-12-24 2021-07-15 InventisBio Co., Ltd. Novel salts of selective estrogen receptor degraders
CN113454077A (zh) 2019-02-22 2021-09-28 爱尔兰詹森科学公司 用于治疗hbv感染或hbv诱发的疾病的酰胺衍生物
EP3959320A1 (en) 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
JP2022532526A (ja) 2019-05-06 2022-07-15 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Ｈｂｖ感染又はｈｂｖ誘導性疾患の処置において有用なアミド誘導体
US11826430B2 (en) 2019-05-14 2023-11-28 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
KR20220044528A (ko) 2019-08-06 2022-04-08 리커리엄 아이피 홀딩스, 엘엘씨 돌연변이체를 치료하기 위한 에스트로겐 수용체 조절제
CA3159749A1 (en) * 2019-11-04 2021-05-14 Recurium Ip Holdings, Llc Salts and forms of an estrogen receptor modulator
EP4058464A1 (en) 2019-11-13 2022-09-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
PE20221724A1 (es) 2019-12-20 2022-11-04 C4 Therapeutics Inc Compuestos de isoindolinona e indazol para la degradacion del receptor del factor de crecimiento epidermico (egfr)
BR112022013322A2 (pt) 2020-01-10 2022-09-20 Jiangsu Hengrui Medicine Co Derivado de tetra-hidroisoquinolina tricíclico, método de preparação para o mesmo e aplicação do mesmo em medicina
AU2021231898A1 (en) 2020-03-05 2022-10-27 C4 Therapeutics, Inc. Compounds for targeted degradation of BRD9
JP2023516291A (ja) 2020-03-06 2023-04-19 オレマ ファーマシューティカルズ インク． エストロゲン受容体関連疾患の治療方法
WO2021253380A1 (en) * 2020-06-19 2021-12-23 InventisBio Co., Ltd. Oral formulations and uses thereof
MX2023001572A (es) * 2020-08-05 2023-05-08 Aizant Drug Res Solutions Private Limited Formas farmaceuticas sólidas de palbociclib.
JP2023551192A (ja) 2020-11-23 2023-12-07 サノフイ 乳がんにおける内分泌療法のモニタリングに使用するためのｅｒ制御遺伝子のパネル
EP4267578A1 (en) 2020-12-23 2023-11-01 Recurium IP Holdings, LLC Estrogen receptor modulators
CA3214408A1 (en) 2021-03-23 2022-09-29 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
EP4334314A1 (en) 2021-05-03 2024-03-13 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
AU2022305957A1 (en) * 2021-07-08 2024-01-25 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
WO2023280309A1 (zh) 2021-07-09 2023-01-12 江苏恒瑞医药股份有限公司 一种三环四氢异喹啉类衍生物的盐型
WO2023221123A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Crystalline forms of an estrogen receptor antagonist
WO2024030968A1 (en) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Compounds for modulating ret protein
WO2024097980A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein inhibitors
WO2024097989A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein degraders

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
AU2381497A (en) 1996-04-19 1997-11-12 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
FR2778404B1 (fr) * 1998-05-06 2000-06-30 Hoechst Marion Roussel Inc Derives du dihydro ou tetrahydronaphtalene, et les compositions pharmaceutiques les renfermant
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
CN1331862C (zh) 1999-04-28 2007-08-15 萨诺费－阿文蒂斯德国有限公司 作为ppar受体配体的二芳基酸衍生物
FR2796644B1 (fr) * 1999-07-23 2001-09-07 Adir Nouveaux derives de beta-carboline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SK13082002A3 (sk) * 2000-03-15 2003-04-01 Aventis Pharma Deutschland Gmbh Substituované beta-karbolíny, spôsob ich prípravy a farmaceutické prostriedky, ktoré ich obsahujú
US6720331B2 (en) 2001-04-03 2004-04-13 National Sun Yat-Sen University 1-substituted 1,2,3,4-tetrahydro-β-carboline and 3,4-dihydro-β-carboline and analogs as antitumor agents
CA2473441A1 (en) 2002-01-18 2003-07-24 The Genetics Company Inc. Beta-secretase inhibitors
ATE404200T1 (de) 2002-04-22 2008-08-15 Univ Johns Hopkins Med Modulatoren von hedgehog signalpfaden, zusammensetzungen und verwandte verwendungen
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
US20050004164A1 (en) 2003-04-30 2005-01-06 Caggiano Thomas J. 2-Cyanopropanoic acid amide and ester derivatives and methods of their use
JP4671123B2 (ja) 2003-06-23 2011-04-13 小野薬品工業株式会社 新規三環性複素環化合物
WO2005012220A2 (en) * 2003-07-28 2005-02-10 Smithkline Beecham Corporation Cycloalkylidene compounds as modulators of estrogen receptor
DE10335725A1 (de) 2003-08-05 2005-03-03 Bayer Cropscience Gmbh Safener auf Basis aromatisch-aliphatischer Carbonsäuredarivate
MXPA06008211A (es) * 2004-01-23 2006-08-31 Chiron Corp Compuestos de tetrahidrocarbolina como agentes anticancer.
JP4051398B2 (ja) * 2004-03-11 2008-02-20 アクテリオン ファマシューティカルズ リミテッド テトラヒドロピリドインドール誘導体
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
WO2006050212A1 (en) 2004-10-28 2006-05-11 The Institutes For Pharmaceutical Discovery Llc Substituted carboxylic acids
EP1836182A2 (en) 2004-11-18 2007-09-26 The Institutes for Pharmaceutical Discovery, LLC Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors
CA2596015A1 (en) 2005-02-14 2006-08-24 Sampath K. Anandan Fused heterocyclic compounds useful as inhibitors of histone deacetylase
WO2006101434A1 (en) * 2005-03-22 2006-09-28 Astrazeneca Ab NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1’ RECEPTOR LIGANDS
US20070032385A1 (en) 2005-06-20 2007-02-08 Dunetz Joshua R Sustainable chemical processes
US20080075692A1 (en) 2006-05-09 2008-03-27 Perrine Susan P Methods for treating blood disorders
ES2648388T3 (es) 2006-08-23 2018-01-02 Kudos Pharmaceuticals Limited Derivados de 2-metilmorfolin pirido-, pirazo- y pirimido-pirimidina como inhibidores de mTOR
WO2008025965A2 (en) 2006-08-29 2008-03-06 Reinnervate Limited Retinoid compounds and their use
WO2008124836A2 (en) 2007-04-10 2008-10-16 Uwm Research Foundation, Inc. Methods of reducing virulence in bacteria
WO2008124838A1 (en) 2007-04-10 2008-10-16 University Of Maryland, Baltimore Compounds that inhibit human dna ligases and methods of treating cancer
JP2010523682A (ja) 2007-04-13 2010-07-15 ピーティーシー セラピューティクス，インコーポレーテッド 癌及び他の疾患の治療に有用なカルボリン誘導体の投与
US20100184758A1 (en) 2007-07-19 2010-07-22 Dobbelaar Peter H Beta carboline derivatives as antidiabetic compounds
CA2728301A1 (en) * 2008-07-03 2010-01-07 Osteogenex Inc. Vinpocetine and eburnamonine derivatives for promoting bone growth
TW201028414A (en) 2009-01-16 2010-08-01 Merck Sharp & Dohme Oxadiazole beta carboline derivatives as antidiabetic compounds
US20120135089A1 (en) 2009-03-17 2012-05-31 Stockwell Brent R E3 ligase inhibitors
EP2434891B9 (en) * 2009-05-27 2021-05-05 PTC Therapeutics, Inc. Methods for treating cancer and non-neoplastic conditions
US20120202801A1 (en) 2009-05-27 2012-08-09 Liangxian Cao Methods for treating breast cancer
US9434747B2 (en) 2011-02-18 2016-09-06 Medivation Technologies, Inc. Methods of treating diabetes
WO2013022740A2 (en) 2011-08-05 2013-02-14 Corning Incorporated Gpr35 ligands and the uses thereof

Also Published As

Publication number Publication date
US20160136140A1 (en) 2016-05-19
US20190038607A1 (en) 2019-02-07
TN2015000516A1 (en) 2017-04-06
CY1120474T1 (el) 2019-07-10
US9616050B2 (en) 2017-04-11
CA2911859A1 (en) 2014-12-04
IL242559B (en) 2018-11-29
PH12015502615A1 (en) 2016-02-29
JP6286031B2 (ja) 2018-02-28
PE20160874A1 (es) 2016-09-04
DK3004090T3 (en) 2018-01-08
AP2015008858A0 (en) 2015-11-30
PT3004090T (pt) 2017-12-22
CN105229004B (zh) 2017-05-03
KR20160013198A (ko) 2016-02-03
PH12015502615B1 (en) 2016-02-29
WO2014191726A1 (en) 2014-12-04
UY35590A (es) 2014-11-28
HK1222859A1 (zh) 2017-07-14
BR112015029455A8 (pt) 2020-03-17
US20170326115A1 (en) 2017-11-16
AU2014272856A1 (en) 2015-11-26
US10130617B2 (en) 2018-11-20
RS56678B1 (sr) 2018-03-30
PL3004090T3 (pl) 2018-02-28
RU2015151502A3 (es) 2018-03-23
EP3004090B1 (en) 2017-10-25
TWI653235B (zh) 2019-03-11
LT3004090T (lt) 2018-01-10
EP3360875A1 (en) 2018-08-15
TW201536779A (zh) 2015-10-01
CL2015003491A1 (es) 2016-06-03
AU2014272856B2 (en) 2017-08-17
SG11201509393VA (en) 2015-12-30
ME02892B (me) 2018-04-20
US9155727B2 (en) 2015-10-13
NI201500167A (es) 2018-10-18
RU2664109C2 (ru) 2018-08-15
CN105229004A (zh) 2016-01-06
HRP20171961T1 (hr) 2018-02-09
EP3004090A1 (en) 2016-04-13
SI3004090T1 (en) 2018-01-31
RU2015151502A (ru) 2017-07-04
BR112015029455A2 (pt) 2017-07-25
JP2016522835A (ja) 2016-08-04
DOP2015000274A (es) 2015-12-31
ES2654161T3 (es) 2018-02-12
MX2015016428A (es) 2016-03-03
US20140357661A1 (en) 2014-12-04
CR20150629A (es) 2016-04-05
HUE035738T2 (en) 2018-05-28

Similar Documents

Publication Publication Date Title
PH12015502615A1 (en) Chemical compounds
TN2015000313A1 (en) Chemical compounds
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
PH12017502141A1 (en) Compounds and their methods of use
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
MD20170070A2 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
PH12016501898A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
MX364486B (es) Derivados de piridazinona-amidas.
PH12018502497A1 (en) Adenosine derivatives for use in the treatment of cancer
PH12015501609A1 (en) Phenicol antibacterials
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
PH12018500446A1 (en) Pyridinone dicarboxamide for use as bromodomain inhibitors
TW201613864A (en) Novel compounds
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
MX2015013936A (es) Compuestos de pirimidina condensada sustituida.
EA032654B9 (ru) [1,2,4]ТРИАЗОЛО[4,3-b]ПИРИДАЗИНЫ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
IN2015DN02109A (es)
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
MX2015009678A (es) Compuestos de pirimidina condensada sustituida con amino en la posicion 4 como inhibidores de fosfodiesterasa 4 (pde4).
MX2017005669A (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.

Legal Events

Date Code Title Description
FG Grant or registration